Potential influence of concomitant medication on Ibrutinib metabolism in patient with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)

Trial Profile

Potential influence of concomitant medication on Ibrutinib metabolism in patient with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Jan 2018

At a glance

  • Drugs Ibrutinib (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Pharmacodynamics
  • Most Recent Events

    • 29 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top